Fabrice Lucien, PhD
@flscientist
Followers
556
Following
2K
Media
97
Statuses
930
🇫🇷🇨🇦🇺🇸 Assistant Professor of Urology & Immunology - Mayo Clinic - Basic and Translational Research - Liquid biopsies and next-gen cancer immunotherapies
Minnesota, USA
Joined December 2016
RT @tompowles1: Kidney injury molecule (KIM-1) is a strongly prognostic circulating biomarker & represents molecular residual disease in r….
0
61
0
RT @MayoUrology: In analysis of over 2,000 open RC patients, Mayo Clinic researchers found that prophylactic iNPWT was associated with lowe….
0
9
0
RT @tompowles1: IMVIGOR011: Atezo vs placebo in ctDNA+ve bladder ca (including -ve becoming +ve) post cystectomy hit OS/PFS. It also tracks….
0
113
0
Delaying the use of ADT in oligorecurrent prostate cancer treated with SBRT but for who? Integration of imaging- and blood-based tumor burden estimation to select the right patients. @MayoUrology @MayoRadOnc @MayoCancerCare .
pubmed.ncbi.nlm.nih.gov
Distant metastasis marks a critical transition in prostate cancer, separating potentially curable from canonically incurable disease. Oligometastatic disease, defined as limited metastases (e.g.,...
2
2
11
RT @MayoUrology: Congrats on @MayoUrology published study led by Drs @VRodriguezBravo and @DomingoDomenech discover that nucleoplasm-residi….
0
12
0
RT @hd_DongMDPhD: Our new humanized both PD-1 and PD-L1 mice are now available at the Jax lab with an RRID. Thank you all for your interest….
0
4
0
😱 Updates on #NCI R01 payline: 4th percentile for EI/NI, 10th %ile for ESI. Awarded R01: 17% budget cuts.R21 payline: 7%ile.
cancer.gov
NCI funding policy for research project grant (RPG) awards reflects the funding goals of the institute, NIH, and HHS.
1
0
0
What does it take to translate urinary EV biomarkers to the clinic? .Glad to have contributed to this excellent review led by Marvin Droste and Uta Erdbrügger in @ISEV_Journals @IsevOrg .
isevjournals.onlinelibrary.wiley.com
Despite remarkable interest in the biomarker potential of urinary extracellular vesicles (uEVs) and the identification of numerous promising candidates, their clinical translation still presents...
0
3
10
RT @urotoday: #PERSIAN trial explores SBRT benefits in oligometastatic hormone-sensitive #ProstateCancer. @GiulioFrancoli1 @AOUCareggi sits….
0
3
0
RT @DDJoyce_BFA: TMT for MIBC is a crucial treatment option for our patients. 💵However, its current costs are u….
0
13
0
RT @czbiohub: 🚫 No dyes. No bleaching. 🔬 Just AI + label-free microscopy = vivid virtually stained images. New in @NatMachIntell: A deep le….
0
85
0
RT @urotoday: Metastasis-directed therapy improves outcomes in oligometastatic #ProstateCancer in #WOLVERINE study. @ChadTangMD @MDAnderson….
0
9
0
RT @Chenghao_Zhu: Our paper on moPepGen is finally out in Nature Biotechnology!.moPepGen is a fast graph-based tool for systematically pred….
0
5
0
RT @VedangMurthy: 2️⃣ Metastasis Directed Therapy in Oligometastatic Prostate Cancer.👥 With @drmaneesh_singh & @piet_ost.🧠 A deep dive into….
0
29
0
Thanks @urotoday for highlighting our recent work on tumor-derived EVs for risk stratification and prediction of response to SBRT in omCSPC @MayoUrology @MayoRadOnc.
PSMA-positive extracellular vesicles as biomarkers in oligometastatic #ProstateCancer. @JackAndrewsMD @MayoClinic joins @zklaassen_md @GACancerCenter to discuss his team's @CCR_AACR publication examining plasma samples from the #ORIOLE trial and #STOMP-protocol patients to
0
5
20
RT @MayoUrology: Congrats to @MayoUrology researchers on their ⭐first-ever exploration of a new frontier in advanced urothelial carcinoma!….
0
16
0
RT @DrMHofman: Stunning research from @EdmondMKwan on ctDNA in theranostics:.🧬Low ctDNA predicts better response with ¹⁷⁷Lu-PSMA-617 vs. ca….
0
45
0
RT @_ShankarSiva: 📢This might just be THE DEFINITIVE meta-analysis of PSMA PET for #prostatecancer recurrence. 🚨Meta-analysis of 43 studie….
0
79
0